Aidan founded the company from an Entrepreneur in Residence position at Oxford Science Enterprises in 2021. Aidan has substantial experience building early stage technology companies as both founder and executive. He was the first business hire and Head of Business Development at Addepar in the US, helping grow the company from $0-50m revenue and >$1bn valuation. Aidan began his career in finance, working for Goldman Sachs’ UK M&A team.

Professor Denison is co-founder and the Chief Engineer of Amber Therapeutics, responsible for leading the company’s technical development and engineering effort. He also holds a joint appointment in Engineering Science and Clinical Neurosciences at Oxford, where he explores the fundamentals of physiologic closed-loop systems. Prior to that, Tim was a Technical Fellow at Medtronic PLC and Vice President of Research & Core Technology for the Restorative Therapies Group, where he helped oversee the design of next generation neural interface and algorithm technologies for the treatment of chronic neurological disease, developing critical sensors and algorithms for commercialized brain and spinal cord-based therapies. ⁠Over 1 million patients have a system with technology he designed. Tim received an A.B. in Physics from The University of Chicago, and an M.S. and Ph.D. in Electrical Engineering from MIT. He recently completed his MBA and was named a Wallman Scholar at The University of Chicago. In 2015, he was elected to the College of Fellows for the American Institute of Medical and Biological Engineering (AIMBE).

Professor De Wachter is co-founder and the Chief Scientist of Amber Therapeutics, responsible for therapy design and clinical innovation. Stefan holds a joint appointment as Head of Urology at Antwerp University Hospital and Professor of Urology at Antwerp University, Belgium. His main research interests address bladder and urethral neurophysiology with a particular focus on novel diagnostics and treatment of urinary dysfunction using neuromodulation approaches (> 200 peer reviewed publications). He is a world recognized innovator in the field of pelvic health and has been a significant contributor to almost all major pivotal trials relevant to advancing new treatments over the last 20 years. Stefan received an MD at Ghent University in 1999 and was awarded European Association of Urology “best thesis” for his PhD in 2004. He was certified as a Fellow of the European Board of Urology in 2012.

Professor Knowles is co-founder and the Chief Medical Officer of Amber Therapeutics, responsible for leading the company’s ambitious clinical trial portfolio. In addition to being a practicing surgeon, he holds several senior academic positions including Professor of Surgery at Queen Mary University of London, Professor of Experimental Therapeutics at University College London and Chief Academic Officer at the Cleveland Clinic London. His main research interests cover the development and evaluation of new technologies for the diagnosis and treatment of chronic bowel diseases (especially neuromodulation and cell therapies). Clinically, he is a key international opinion leader on pelvic floor disorders with a focus on incontinence. Charles qualified from the University of Cambridge and undertook general surgical training and a PhD in London. He became a Fellow of the Royal College of Surgeons in 1996 and was certified as a specialist colorectal surgeon in 2005. He was awarded an honorary fellowship of the American Society of Colon and Rectal Surgeons in 2021 reflecting his international contributions to research (> 300 peer reviewed publications), major general and colorectal surgical textbooks, guidance and policy documents.

Iain is Amber’s Vice President of Regulatory, Clinical & Quality, joining with over 15 years experience in the medical device industry in both start-up companies and large multinationals. His experience covers class II and III implantables, including combination device drug products. Most recently Iain served as a board Director at RUA Life Sciences PLC with responsibility for Clinical, Regulatory and Quality. Prior to this he was Director of Pre-clinical and Clinical Regulatory Affairs at MedAlliance LLC following his role as Head of Clinical Affairs at Terumo Aortic. Iain has expertise in clinical trial design and clinical operations execution, including designing novel clinical trials for FDA submissions, and EU pre- and post-market trials. He has experience of both US and EU medical device regulatory affairs in addition to experience of implementing and developing ISO13485 Quality Management Systems. Iain has a PhD in Neurovirology and Neuropathology from the University of Edinburgh and has over 40 peer reviewed publications.

Tomás Furey is Vice President of Operations of Amber Therapeutics. Trained originally as a manufacturing engineer, Tomás has more than twenty five years of experience in medical device development and manufacturing. He began his career in medtech in process re-engineering at Boston Scientific. He has since held senior operational roles in Lake Region Medical, Vyaire Medical and Balt Medical. He has a particular interest in process excellence and the application of lean business techniques and has held several successful roles in operations management, quality and regulatory affairs.